205 related articles for article (PubMed ID: 22746187)
1. Colloidal carriers: a rising tool for therapy of tuberculosis.
Gupta S; Kumar P; Gupta MK; Vyas S
Crit Rev Ther Drug Carrier Syst; 2012; 29(4):299-53. PubMed ID: 22746187
[TBL] [Abstract][Full Text] [Related]
2. New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery.
Sosnik A; Carcaboso AM; Glisoni RJ; Moretton MA; Chiappetta DA
Adv Drug Deliv Rev; 2010 Mar; 62(4-5):547-59. PubMed ID: 19914315
[TBL] [Abstract][Full Text] [Related]
3. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
4. A review of emerging trends in the treatment of tuberculosis.
Kaur M; Garg T; Narang RK
Artif Cells Nanomed Biotechnol; 2016; 44(2):478-84. PubMed ID: 25365354
[TBL] [Abstract][Full Text] [Related]
5. Inhalable porous particles as dual micro-nano carriers demonstrating efficient lung drug delivery for treatment of tuberculosis.
Campos Pacheco JE; Yalovenko T; Riaz A; Kotov N; Davids C; Persson A; Falkman P; Feiler A; Godaly G; Johnson CM; Ekström M; Pilkington GA; Valetti S
J Control Release; 2024 May; 369():231-250. PubMed ID: 38479444
[TBL] [Abstract][Full Text] [Related]
6. Targeting pulmonary tuberculosis using nanocarrier-based dry powder inhalation: current status and futuristic need.
Patil TS; Deshpande AS; Deshpande S; Shende P
J Drug Target; 2019 Jan; 27(1):12-27. PubMed ID: 29561179
[TBL] [Abstract][Full Text] [Related]
7. Nano-carriers for the Treatment of Tuberculosis.
Gilani SJ; Ameeduzzafar ; Jafar M; Shakil K; Imam SS
Recent Pat Antiinfect Drug Discov; 2017; 12(2):95-106. PubMed ID: 28595544
[TBL] [Abstract][Full Text] [Related]
8. Particulate and vesicular drug carriers in the management of tuberculosis.
Rastogi R; Sultana Y; Ali A; Aqil M
Curr Drug Deliv; 2006 Jan; 3(1):121-8. PubMed ID: 16472101
[TBL] [Abstract][Full Text] [Related]
9. Dry powder inhalers of antitubercular drugs.
Nainwal N; Sharma Y; Jakhmola V
Tuberculosis (Edinb); 2022 Jul; 135():102228. PubMed ID: 35779497
[TBL] [Abstract][Full Text] [Related]
10. How can nanoparticles contribute to antituberculosis therapy?
Costa-Gouveia J; Aínsa JA; Brodin P; Lucía A
Drug Discov Today; 2017 Mar; 22(3):600-607. PubMed ID: 28137645
[TBL] [Abstract][Full Text] [Related]
11. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis.
Pandey R; Sharma A; Zahoor A; Sharma S; Khuller GK; Prasad B
J Antimicrob Chemother; 2003 Dec; 52(6):981-6. PubMed ID: 14613962
[TBL] [Abstract][Full Text] [Related]
12. Nanostructured Therapeutic Carriers for Tuberculosis Treatment: Approaches & Challenges.
Ullah Z; Athar MT; Samad A
Recent Pat Antiinfect Drug Discov; 2017; 12(2):128-137. PubMed ID: 28990537
[TBL] [Abstract][Full Text] [Related]
13. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis.
Sharma A; Sharma S; Khuller GK
J Antimicrob Chemother; 2004 Oct; 54(4):761-6. PubMed ID: 15329364
[TBL] [Abstract][Full Text] [Related]
14. [Prospects for development of new antituberculous drugs].
Tomioka H
Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
[TBL] [Abstract][Full Text] [Related]
15. Dry powder inhalable formulations for anti-tubercular therapy.
Parumasivam T; Chang RY; Abdelghany S; Ye TT; Britton WJ; Chan HK
Adv Drug Deliv Rev; 2016 Jul; 102():83-101. PubMed ID: 27212477
[TBL] [Abstract][Full Text] [Related]
16. Tuberculosis: from molecular pathogenesis to effective drug carrier design.
Dube D; Agrawal GP; Vyas SP
Drug Discov Today; 2012 Jul; 17(13-14):760-73. PubMed ID: 22480870
[TBL] [Abstract][Full Text] [Related]
17. Emerging role of vesicular carriers for therapy of visceral leishmaniasis: conventional versus novel.
Kumar N; Gupta S; Dube A; Vyas SP
Crit Rev Ther Drug Carrier Syst; 2010; 27(6):461-507. PubMed ID: 21175419
[TBL] [Abstract][Full Text] [Related]
18. Advances in nanotechnology for diagnosis and treatment of tuberculosis.
Banyal S; Malik P; Tuli HS; Mukherjee TK
Curr Opin Pulm Med; 2013 May; 19(3):289-97. PubMed ID: 23429097
[TBL] [Abstract][Full Text] [Related]
19. Nano-based drug delivery optimization for tuberculosis treatment: A review.
Dahanayake MH; Jayasundera ACA
J Microbiol Methods; 2021 Feb; 181():106127. PubMed ID: 33359155
[TBL] [Abstract][Full Text] [Related]
20. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
